Loading...
Patients with inflammatory bowel disease (IBD) have low serum concentrations of dipeptidyl peptidase-4 (DPP-4) enzyme, which is associated inversely with disease activity. Researchers conducted a population-based cohort study of >140,000 U.K. adults with type 2 diabetes to investigate whether DPP-4 inhibitors (gliptins) are associated with excess risk for IBD.
Among patients who initiated noninsulin antidiabetes drugs, 208 new IBD events occurred during average follow-up of 3.6 years. In an analysis adjusted for multiple potential confounders, gliptins were associated with significant excess risk for IBD compared with other antidiabetes drugs (53 vs. 34 events per 100,000 person-years; hazard ratio, 1.8). Relative risk peaked at 3 to 4 years…